Shorepoint Capital Partners LLC Takes Position in Thermo Fisher Scientific Inc. (TMO)

Shorepoint Capital Partners LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,125 shares of the medical research company’s stock, valued at approximately $1,676,000.

Other large investors have also made changes to their positions in the company. CX Institutional purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $36,000. Freestone Capital Holdings LLC raised its holdings in shares of Thermo Fisher Scientific by 46.1% in the fourth quarter. Freestone Capital Holdings LLC now owns 10,081 shares of the medical research company’s stock valued at $2,256,000 after buying an additional 3,180 shares during the last quarter. Putnam FL Investment Management Co. raised its holdings in shares of Thermo Fisher Scientific by 2.9% in the fourth quarter. Putnam FL Investment Management Co. now owns 29,001 shares of the medical research company’s stock valued at $6,490,000 after buying an additional 810 shares during the last quarter. Calamos Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 5.4% in the fourth quarter. Calamos Advisors LLC now owns 132,462 shares of the medical research company’s stock valued at $29,644,000 after buying an additional 6,769 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Handelsbanken Fonder AB now owns 367,354 shares of the medical research company’s stock valued at $82,210,000 after buying an additional 14,789 shares during the last quarter. 88.66% of the stock is owned by institutional investors and hedge funds.

NYSE TMO opened at $280.65 on Monday. The stock has a market cap of $111.92 billion, a P/E ratio of 25.24, a PEG ratio of 1.85 and a beta of 1.13. Thermo Fisher Scientific Inc. has a 52-week low of $202.83 and a 52-week high of $282.98. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.73 and a quick ratio of 1.24.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 30th. The medical research company reported $3.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.19 by $0.06. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.26 billion. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.79 earnings per share. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 12.15 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 16th. Investors of record on Friday, March 15th will be issued a dividend of $0.19 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. This represents a $0.76 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 6.83%.

In other Thermo Fisher Scientific news, CAO Peter E. Hornstra sold 5,920 shares of the company’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $250.00, for a total transaction of $1,480,000.00. Following the transaction, the chief accounting officer now directly owns 17,057 shares in the company, valued at $4,264,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $266.00, for a total transaction of $665,000.00. The disclosure for this sale can be found here. Insiders have sold 36,927 shares of company stock valued at $9,388,124 over the last three months. 0.49% of the stock is currently owned by corporate insiders.

A number of brokerages have recently commented on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $310.00 target price for the company in a report on Tuesday, April 9th. Robert W. Baird upped their target price on shares of Thermo Fisher Scientific from $264.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 30th. BTIG Research upped their target price on shares of Thermo Fisher Scientific to $310.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Deutsche Bank upped their target price on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the company a “buy” rating in a report on Friday, March 22nd. Finally, UBS Group increased their price target on shares of Thermo Fisher Scientific to $305.00 and gave the stock a “buy” rating in a report on Monday, March 25th. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $289.00.

COPYRIGHT VIOLATION NOTICE: This report was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2019/04/15/shorepoint-capital-partners-llc-takes-position-in-thermo-fisher-scientific-inc-tmo.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: Quick Ratio

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.